ResMed sells MatrixCare business for $490M
ResMed (ASX:RMD) signed an agreement to sell its MatrixCare software business to private equity firm Frazier Healthcare Partners.
Todas as matérias desta categoria, das mais recentes às mais antigas.
ResMed (ASX:RMD) signed an agreement to sell its MatrixCare software business to private equity firm Frazier Healthcare Partners.
Imugene (ASX:IMU) secured firm commitments to raise $11.1 million via a share placement to fund its cancer clinical trials.
Argent BioPharma (ASX:RGT) executed a binding transaction framework for the exclusive global licensing of its epilepsy asset CannEpil.
Entropy Neurodynamics (ASX:ENP) reported that all patients in its initial trial cohort achieved a 74% reduction in binge eating episodes.
Osteopore (ASX:OSX) secured market access to Saudi Arabia to commercialise its 3D-printed craniofacial implants in partnership with Zimmer Biomet (NYSE:ZBH).
Clinical-stage company Syntara (ASX:SNT) announced that 20 of 30 patients recorded lower brain inflammation from baseline.
ReNerve (ASX:RNV) obtained marketing approval for its NervAlign Nerve Cuff in Indonesia
OncoSil Medical (ASX:OSL) has completed its Humanitarian Device Exemption application submission to the US FDA.
Echo IQ (ASX:EIQ) executed an exclusive agreement to license up to 1 million de-identified echocardiography studies from Advara HeartCare.
Genetic Signatures (ASX:GSS) received no advance notification regarding a 10.2% stake acquisition by BCAL Diagnostics (ASX:BDX).
Imugene (ASX:IMU) announced a second complete response within 24 hours in its concurrent combination trial cohort.
Telix Pharmaceuticals (ASX:TLX) aligned with the US regulator to advance its Phase 3 trial after a 36-patient safety study.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade